KyungDong Pharm Co., Ltd. launched the NSAIDs+PPI combination drug ‘Nasopra Tablet’ on July 1, 2025.

 

Nasopra tablets are a combination drug that combines the NSAIDs (non-steroidal anti-inflammatory drug) naproxen and the PPI (proton pump inhibitor) esomeprazole. While maintaining the anti-inflammatory analgesic effect, the risk of gastrointestinal side effects that can occur when taking NSAIDs is significantly lowered.


The most notable feature is that the esomeprazole component is released first in immediate-release form to regulate pH in the gastrointestinal tract, and the enteric-coated naproxen component acts in the small intestine.

The dosage is to take 1 tablet orally twice a day. It should be swallowed with water without splitting, chewing, or crushing. It is recommended to take it at least 30 minutes before a meal.

As demand for prescriptions for NSAIDs+PPI combination drugs is gradually increasing,

It is expected to provide more diverse treatment options to medical staff and patients.


□ Product information

▶ Product name: Nasopra tablet
▶ Ingredients/Content: Naproxen 500mg + Esomeprazole 20mg
▶ Efficacy/Effectiveness: Patients with risk of gastric ulcer and duodenal ulcer related to non-steroidal anti-inflammatory drugs (NSAIDs)
Treatment of symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis
▶ Usage/Dosage: 2 times a day, 1 tablet per time
▶ Packaging unit: 30 tablets/bottle, 100 tablets/bottle
▶ Dosage form: Oval-shaped, yellow film-coated tablet with convex sides, consisting of a core and an outer core.